Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Marker Therapeutics Inc MRKR

Healthcare Biotechnology
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered... see more

Recent & Breaking News (NDAQ:MRKR)

TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform

PR Newswire May 15, 2018

TapImmune to Present at 2018 NYC Oncology Investor Conference

PR Newswire May 7, 2018

TapImmune to Present at 2018 Disruptive Growth & Healthcare Conference

PR Newswire May 1, 2018

TapImmune Provides Fourth Quarter and Year-End 2017 Corporate and Clinical Update

PR Newswire April 5, 2018

TapImmune to Provide Fourth Quarter and Full Year 2017 Business Update Conference Call and Webcast

PR Newswire March 29, 2018

TapImmune to Present at The MicroCap Conference

Accesswire March 28, 2018

TapImmune Announces Publication of Clinical Trial Results for the TPIV200 Cancer Vaccine in Clinical Cancer Research

PR Newswire March 15, 2018

TapImmune to Present at Two Upcoming Investor Conferences

PR Newswire March 14, 2018

TapImmune to Participate in Two Upcoming Investor Conferences

PR Newswire February 6, 2018

TapImmune to Present at Biotech Showcase™ 2018

PR Newswire January 3, 2018

TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negative Breast Cancer Funded by U.S. Department of Defense

PR Newswire December 12, 2017

TapImmune, Inc. Presentation Now Available for On-Demand Viewing

PR Newswire December 11, 2017

TapImmune Appoints Richard Kenney, M.D., F.A.C.P., as Acting Chief Medical Officer

PR Newswire December 6, 2017

TapImmune Inc. to Webcast, Live, at VirtualInvestorConferences.com December 7

PR Newswire December 4, 2017

Live Investor Conference & Webinar: NASDAQ, NYSE and OTC companies present December 7th

PR Newswire December 4, 2017

TapImmune to Present at 29th Annual Piper Jaffray Healthcare Conference

PR Newswire November 21, 2017

TapImmune to Present at World Vaccine & Immunotherapy Congress West Coast

PR Newswire November 17, 2017

TapImmune Provides Third Quarter 2017 Corporate and Clinical Update

PR Newswire November 15, 2017

TapImmune Inc. to Host Earnings Call

Accesswire November 15, 2017

TapImmune Completes Patient Enrollment Ahead of Schedule in Phase 2 Cancer Vaccine Study for Treating Triple-Negative Breast Cancer

PR Newswire November 14, 2017